EPO and chronic kidney disease: Phase 3 clinical trials in CKD patients reported that alongside the primary outcomes to increase haemoglobin and erythropoietin levels, at least some PHDi (i.e. roxadustat, dabrodustat) can lower cholesterol and low-density lipoprotein cholesterol levels47,48.